Keymed Biosciences Inc. will convene its board of directors on 19 August 2026 to review and approve the interim financial statements for the six months ended 30 June 2026. The agenda also includes deliberation on the declaration of an interim dividend, if any.
The meeting was announced on 7 August 2026. Keymed Biosciences’ board is led by Chairman Dr. Bo Chen and comprises three executive directors, three non-executive directors and three independent non-executive directors.